A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis
Public ClinicalTrials.gov record NCT03384745. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b Randomized, Double-blind, Placebo Controlled, Multi-center 12-week Study With an Additional 40-week Follow-up Assessment of Efficacy, Safety and Tolerability of M1095 in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Study identification
- NCT ID
- NCT03384745
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bond Avillion 2 Development LP
- Industry
- Enrollment
- 313 participants
Conditions and interventions
Conditions
Interventions
- M1095 (Sonelokimab) Drug
- Placebo Drug
- Secukinumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 30, 2018
- Primary completion
- Jun 19, 2019
- Completion
- Mar 25, 2020
- Last update posted
- Aug 2, 2021
2018 – 2020
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigative Site | Birmingham | Alabama | 35205 | — |
| Investigative Site | San Diego | California | 92123 | — |
| Investigative Site | DeLand | Florida | 32720 | — |
| Investigative Site | Sandy Springs | Georgia | 30328 | — |
| Investigative Site | St Louis | Missouri | 63117 | — |
| Investigative Site | Albuquerque | New Mexico | 87102 | — |
| Investigative Site | New York | New York | 10029 | — |
| Investigative Site | Bexley | Ohio | 43209 | — |
| Investigative Site | Dallas | Texas | 75246 | — |
| Investigative Site | Houston | Texas | 77004 | — |
| Investigative Site | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03384745, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 2, 2021 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03384745 live on ClinicalTrials.gov.